Izalontamab SI-B001: An Encouraging Emerging Immunoglobulin Approach
This antibody SI-B001 is a significant development in the management of refractory multiple myeloma. The innovative antibody specifically binds to BCMA within myeloma cells, triggering antibody-dependent cellular cytotoxicity and enhancing cancer-inhibiting patient's responses. Early clinical dat